Reports
Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The global Hodgkin’s lymphoma treatment market reached a value of about USD 1.1 billion in 2021. The market is further estimated to grow at a CAGR of 13.40% in the forecast period of 2023-2028 to reach a value of around USD 2.3 billion by 2027.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on the treatment type, the radiotherapy segment holds significant market share of Hodgkin’s lymphoma treatment. The growing awareness about the effectiveness of radiotherapy in killing Hodgkin’s lymphoma cells is contributing to the steady market growth. Radiotherapy is painless, and the treatment is administered in short sessions that require no hospital stay, thereby accelerating the market development. In addition, radiotherapy can be given along with surgery, chemotherapy, hormones, or targeted therapy, which offers the patients with wide choices to treat the disease completely, thus bolstering the market. The availability of modern imaging tests that enables the doctors to aim at the lymphoma sites precisely can help limit side effects, which plays a critical role in expanding the market for Hodgkin’s lymphoma treatment. The rising inclination of healthcare professionals towards newer approaches to radiation, such as Involved site radiation therapy (ISRT), which reduces the size of the treatment area and helps spare nearby normal tissues from getting radiation, is leading to the market growth of Hodgkin’s lymphoma treatment.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Hodgkin’s lymphoma is a type of cancer that spreads through the lymph vessels from lymph node to lymph node. The cancer in an advanced stage, though rarely, can invade the bloodstream and spread to other body parts, such as the liver, lungs, and bone marrow. There are two types of Hodgkin’s lymphoma - Classic Hodgkin lymphoma (cHL) and Nodular lymphocyte. The predominant treatments offered to cure the disease are chemotherapy, and radiotherapy, among others.
The market for Hodgkin’s lymphoma treatment, by treatment type, is divided into:
The regional markets for Hodgkin’s lymphoma treatment can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The increasing prevalence of Hodgkin’s Lymphoma disease is leading to the market development of Hodgkin’s Lymphoma treatment. In 2019, about 218,740 people were living with Hodgkin lymphoma in the United States, and the region witnessed an estimated increase of 8,540 cases in 2022. The developing healthcare infrastructure and the rapid diagnosis of the disease are contributing to the market expansion of Hodgkin’s Lymphoma treatment. The growing awareness about the increased recovery chance of the disease among the people and the importance of treatments in it is further propelling the market for Hodgkin’s Lymphoma treatment. The government initiatives in approving novel drugs to treat Hodgkin’s Lymphoma play a critical role in expanding the market. In 2018, the U.S. FDA approved Adcetris (brentuximab vedotin) to treat adult patients with earlier untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. The development of efficient therapies due to the research activities and the rising clinical trials is expected to augment the market for Hodgkin’s lymphoma treatment over the forecast period.
The report gives a detailed analysis of the following key players in the global Hodgkin’s lymphoma treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2022 |
Historical Period | 2018-2022 |
Forecast Period | 2023-2028 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Treatment Type |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Hodgkin’s Lymphoma Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Hodgkin’s Lymphoma Treatment Historical Market (2018-2022)
8.3 Global Hodgkin’s Lymphoma Treatment Market Forecast (2023-2028)
8.4 Global Hodgkin’s Lymphoma Treatment Market by Treatment Type
8.4.1 Chemotherapy
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 Radiotherapy
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 Others
8.5 Global Hodgkin’s Lymphoma Treatment Market by Region
8.5.1 Market Share
8.5.1.1 North America
8.5.1.2 Europe
8.5.1.3 Asia Pacific
8.5.1.4 Latin America
8.5.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2022)
9.3.2 Forecast Trend (2023-2028)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2022)
9.4.2 Forecast Trend (2023-2028)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2022)
9.5.2 Forecast Trend (2023-2028)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Alkem Laboratories
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Amneal Pharmaceuticals, Inc.
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 Baxter International Inc.
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 Biogen Inc.
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Bristol-Myers Squibb Company
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 F Hoffmann-La Roche Ltd
11.2.6.1 Company Overview
11.2.6.2 Product Portfolio
11.2.6.3 Demographic Reach and Achievements
11.2.6.4 Certifications
11.2.7 Incyte Corp.
11.2.7.1 Company Overview
11.2.7.2 Product Portfolio
11.2.7.3 Demographic Reach and Achievements
11.2.7.4 Certifications
11.2.8 Others
12 Industry Events and Developments
List of Figures and Tables
1. Global Hodgkin’s Lymphoma Treatment Market: Key Industry Highlights, 2018 and 2028
2. Global Hodgkin’s Lymphoma Treatment Historical Market: Breakup by Treatment Type (USD Billion), 2018-2022
3. Global Hodgkin’s Lymphoma Treatment Market Forecast: Breakup by Treatment Type (USD Billion), 2023-2028
4. Global Hodgkin’s Lymphoma Treatment Historical Market: Breakup by Region (USD Billion), 2018-2022
5. Global Hodgkin’s Lymphoma Treatment Market Forecast: Breakup by Region (USD Billion), 2023-2028
6. North America Hodgkin’s Lymphoma Treatment Historical Market: Breakup by Country (USD Billion), 2018-2022
7. North America Hodgkin’s Lymphoma Treatment Market Forecast: Breakup by Country (USD Billion), 2023-2028
8. Europe Hodgkin’s Lymphoma Treatment Historical Market: Breakup by Country (USD Billion), 2018-2022
9. Europe Hodgkin’s Lymphoma Treatment Market Forecast: Breakup by Country (USD Billion), 2023-2028
10. Asia Pacific Hodgkin’s Lymphoma Treatment Historical Market: Breakup by Country (USD Billion), 2018-2022
11. Asia Pacific Hodgkin’s Lymphoma Treatment Market Forecast: Breakup by Country (USD Billion), 2023-2028
12. Latin America Hodgkin’s Lymphoma Treatment Historical Market: Breakup by Country (USD Billion), 2018-2022
13. Latin America Hodgkin’s Lymphoma Treatment Market Forecast: Breakup by Country (USD Billion), 2023-2028
14. Middle East and Africa Hodgkin’s Lymphoma Treatment Historical Market: Breakup by Country (USD Billion), 2018-2022
15. Middle East and Africa Hodgkin’s Lymphoma Treatment Market Forecast: Breakup by Country (USD Billion), 2023-2028
16. Global Hodgkin’s Lymphoma Treatment Market Structure
In 2021, the global Hodgkin’s lymphoma treatment market attained a value of nearly USD 1.1 billion.
The market is assessed to grow at a CAGR of 13.40% between 2023 and 2028.
The market is estimated to witness a healthy growth in the forecast period of 2023-2028 to reach almost USD 2.3 billion by 2027.
The major market drivers include the increased recovery chances through effective treatments, rapid diagnosis of the disease, developing healthcare infrastructure, and growing awareness about the different treatments available to cure the disease.
The key market trends include government initiatives in approving drugs, and research activities done to develop new therapies and drugs.
The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The various treatment types of Hodgkin’s lymphoma treatment, include chemotherapy, and radiotherapy, among others.
The major players in the market are Alkem Laboratories, Amneal Pharmaceuticals, Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, F Hoffmann-La Roche Ltd, and Incyte Corp., among others.
The global Hodgkin’s lymphoma treatment market attained a value of nearly USD 1.1 billion in 2021, driven by the prevalence of Hodgkin’s lymphoma and rising treatment development for increased recovery rate. Aided by the development of new drugs and therapies, the market is expected to witness a further growth in the forecast period of 2023-2028, growing at a CAGR of 13.40%. The market is estimated to reach about USD 2.3 billion by 2027.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The market for Hodgkin’s lymphoma treatment, by treatment type, is divided into chemotherapy, and radiotherapy, among others. The major regional markets for Hodgkin’s lymphoma treatment are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Alkem Laboratories, Amneal Pharmaceuticals, Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, F Hoffmann-La Roche Ltd, and Incyte Corp., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.